Macro Group Pharmaceuticals (Macro Capital) S.A.E (EGX:MCRO)
Egypt
· Delayed Price · Currency is EGP 1.340
-0.040 (-2.90%)
At close: Mar 9, 2026
EGX:MCRO Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | 894.54 | 519.97 | 526.01 | 729.61 | 594.26 | Upgrade
|
| Revenue Growth (YoY) | 72.04% | -1.15% | -27.91% | 22.78% | 38.04% | Upgrade
|
| Cost of Revenue | 285.3 | 196.85 | 230.36 | 167.97 | 120.39 | Upgrade
|
| Gross Profit | 609.24 | 323.12 | 295.65 | 561.64 | 473.87 | Upgrade
|
| Selling, General & Admin | 428.35 | 274.82 | 353.03 | 314.18 | 256.02 | Upgrade
|
| Other Operating Expenses | 15.86 | 0.59 | 26.57 | 9.96 | 13.73 | Upgrade
|
| Operating Expenses | 473.79 | 311.09 | 478.04 | 327.29 | 270.25 | Upgrade
|
| Operating Income | 135.45 | 12.03 | -182.39 | 234.35 | 203.62 | Upgrade
|
| Interest Expense | -34.43 | -60.65 | -29.48 | -13.48 | -8.15 | Upgrade
|
| Interest & Investment Income | 9.39 | 5.77 | 1.98 | 2.8 | 1.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 11.48 | - | 14.23 | 3.68 | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -49.95 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 121.89 | -42.85 | -245.62 | 227.35 | 196.46 | Upgrade
|
| Impairment of Goodwill | - | - | -21.42 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3.29 | - | - | - | Upgrade
|
| Asset Writedown | - | - | -3 | - | - | Upgrade
|
| Pretax Income | 121.89 | -39.56 | -270.03 | 227.35 | 196.46 | Upgrade
|
| Income Tax Expense | 6.07 | -1.51 | 2.6 | 53.48 | 48.49 | Upgrade
|
| Earnings From Continuing Operations | 115.82 | -38.04 | -272.64 | 173.88 | 147.97 | Upgrade
|
| Minority Interest in Earnings | -0.09 | -0.05 | -0.01 | -0.04 | -0.04 | Upgrade
|
| Net Income | 115.73 | -38.1 | -272.65 | 173.84 | 147.93 | Upgrade
|
| Net Income to Common | 115.73 | -38.1 | -272.65 | 173.84 | 147.93 | Upgrade
|
| Net Income Growth | - | - | - | 17.51% | 9.47% | Upgrade
|
| Shares Outstanding (Basic) | 570 | 570 | 564 | 572 | 577 | Upgrade
|
| Shares Outstanding (Diluted) | 570 | 570 | 564 | 572 | 577 | Upgrade
|
| Shares Change (YoY) | - | 1.12% | -1.46% | -0.88% | - | Upgrade
|
| EPS (Basic) | 0.20 | -0.07 | -0.48 | 0.30 | 0.26 | Upgrade
|
| EPS (Diluted) | 0.20 | -0.07 | -0.48 | 0.30 | 0.26 | Upgrade
|
| EPS Growth | - | - | - | 17.09% | 11.40% | Upgrade
|
| Free Cash Flow | 118.51 | -86.76 | -44.44 | 129.63 | 44.44 | Upgrade
|
| Free Cash Flow Per Share | 0.21 | -0.15 | -0.08 | 0.23 | 0.08 | Upgrade
|
| Dividend Per Share | - | - | - | 0.107 | 0.069 | Upgrade
|
| Dividend Growth | - | - | - | 54.70% | - | Upgrade
|
| Gross Margin | 68.11% | 62.14% | 56.21% | 76.98% | 79.74% | Upgrade
|
| Operating Margin | 15.14% | 2.31% | -34.67% | 32.12% | 34.26% | Upgrade
|
| Profit Margin | 12.94% | -7.33% | -51.83% | 23.83% | 24.89% | Upgrade
|
| Free Cash Flow Margin | 13.25% | -16.69% | -8.45% | 17.77% | 7.48% | Upgrade
|
| EBITDA | 140.42 | 16.6 | -175.19 | 237.89 | 206.04 | Upgrade
|
| EBITDA Margin | 15.70% | 3.19% | -33.31% | 32.61% | 34.67% | Upgrade
|
| D&A For EBITDA | 4.97 | 4.57 | 7.2 | 3.54 | 2.42 | Upgrade
|
| EBIT | 135.45 | 12.03 | -182.39 | 234.35 | 203.62 | Upgrade
|
| EBIT Margin | 15.14% | 2.31% | -34.67% | 32.12% | 34.26% | Upgrade
|
| Effective Tax Rate | 4.98% | - | - | 23.52% | 24.68% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.